Biomind LabsNEO/CBOE: BMND | OTC: BMNDF | Frankfurt: 3XI

Actual: May 1, 2023

Phase 2a trial began (depression/anxiety in Alzheimer's patients)

Why it matters: BMND08 is a 5-MeO-DMT sublingual formulation — a very short-duration psychedelic (15–30 min experience) versus psilocybin (4–6 hours). This brevity may be particularly important for Alzheimer's patients who cannot tolerate long supervised sessions.

Actual: Feb 29, 2024

Phase 2 results: 100% of participants responded; 100% achieved remission from depression, anxiety, and stress by Week 5; safe and efficacious at max 12 mg once weekly x4 weeks (NCT06816667)

Why it matters: 100% response and remission in an Alzheimer's psychiatric symptoms trial is an extraordinary signal. While the sample size was small, complete remission in a population with severe, treatment-resistant neuropsychiatric symptoms positions BMND08 for Breakthrough Therapy Designation, which would dramatically accelerate the regulatory pathway.

Watch next: Breakthrough Therapy Designation application result; Phase 3 trial design and initiation

Actual: Dec 1, 2025

FDA pathway accelerated for nano-formulation BMND08 (proprietary nano-formulation of 5-MeO-DMT)

Why it matters: A proprietary nano-formulation improves drug solubility, bioavailability, and dosing precision — potentially enabling more consistent plasma levels than the sublingual formulation and strengthening the IP position for Phase 3.

Watch next: Breakthrough Therapy Designation decision and Phase 3 design announcement

Actual: Jul 1, 2024

BMND06 indication pivot: new target announced — neurological pathway for obesity

Why it matters: Mescaline's 5-HT2C agonism is hypothesised to influence satiety signalling — a mechanism shared by lorcaserin and other appetite-suppressant serotonergic drugs. Repurposing to obesity represents an enormous market expansion opportunity, though the mechanism requires preclinical validation.

Watch next: Preclinical obesity efficacy data and IND-enabling study design